Cefepime-Taniborbactam Beats Meropenem for Treating cUTI in Phase 3 TrialOctober 27th 2022
Venatorx Pharmaceuticals is advancing the fight against difficult-to-treat, drug-resistant, gram-negative bacteria with a successful phase 3 clinical trial of its investigational antibiotic cefepime-taniborbactam.
Utilizing Rapid Diagnostics and DRIP Scores Together to Tailor Therapy and Enhance StewardshipOctober 25th 2022
Using the DRIP Score along with newer diagnostic technology may determine the course of antibiotics for certain patients with pneumonia more efficiently and efficaciously.
Reevaluating Susceptibility BreakpointsOctober 24th 2022
After the Clinical and Laboratory Standards Institute (CLSI) revised their clinical breakpoints for susceptibility test results, a laboratory at a major medical center in a large midwest city evaluated enterobacterales as it relates to bloodstream infections (BSI) and piperacillin/tazobactam.
ERADICATE: Ceftobiprole Noninferior to Daptomycin for Complicated Staphylococcus aureus BacteremiaOctober 22nd 2022
The phase 3 study met its primary and secondary end points of all-cause mortality, microbiological eradication rates, and new Staphylococcus aureus bacteremia complications.